循环肿瘤细胞在肺癌诊疗中的临床应用与进展
|
摘要
近几年来在肺癌治疗中非侵入性的"液体活检"被不断开发和研究,作为新型生物标志物循环肿瘤细胞(CTC)更是得到研究者们的广泛关注。对肺癌患者具有灵敏度和特异性的CTC进行富集分析,这为深入了解肺癌的生物学以及转移过程提供了有力机会。CTC的分析及实时监测对肺癌患者的早期诊断、治疗、耐药性的评估及预测预后都具有重要价值。本文将对目前CTC在肺癌诊疗中的临床应用与进展做简要阐述和讨论。
引文
[1]GROUP N M C.Preoperative chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual participant data[J].Lancet,2014,383(9928):1561-1571.
[2]ESPOSITO A,CRISCITIELLO C,LOCATELLI M,et al.Liquid biopsies for solid tumors:understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies[J].Pharmacol Ther,2016,157:120-124.
[3]GERLINGER M,ROWAN A J,HORSWELL S,et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J].New Engl J Med,2012,366(10):883-892.
[4]MATIKAS A,SYRIGOS K N,AGELAKI S.Circulating biomarkers in non-small-cell lung cancer:current status and future challenges[J].Clin Lung Cancer,2016,17(6):507-516.
[5]TARTARONE A,ROSSI E,LEROSE R,et al.Possible applications of circulating tumor cells in patients with non small cell lung cancer[J].Lung Cancer,2017,107:59-64.
[6]ASHWORTH T R.A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J].Aust Med J,1869,14:146.
[7]BULFONI M,TURETTA M,DEL BEN F,et al.Dissecting the heterogeneity of circulating tumor cells in metastatic breast cancer:going far beyond the needle in the haystack[J].Int J Mol Sci,2016,17(10).pii:E1775.
[8]ALIX-PANABIèRES C,PANTEL K.Challenges in circulating tumour cell research[J].Nat Rev Cancer,2014,14(9):623-631.
[9]ALIX-PANABIèRES C,PANTEL K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J].Cancer discov,2016,6(5):479-491.
[10]PéREZ-CALLEJO D,ROMERO A,PROVENCIO M,et al.Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring[J].Transl Lung Cancer Res,2016,5(5):455-465.
[11]TURETTA M,BULFONI M,BRISOTTO G,et al.Assessment of the mutational status of nsclc using hypermetabolic circulating tumor cells[J].Cancers,2018,10(8).pii:E270.
[12]MOK T S,WU Y L,AHN M J,et al.Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer[J].New Engl J Med,2017,376(7):629-640.
[13]PUNNOOSE E A,ATWAL S,LIU W,et al.Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:Association with clinical endpoints in a phase IIclinical trial of pertuzumab and erlotinib[J].Clin Cancer Res,2012,18(8):2391-2401.
[14]BREITENBUECHER F,HOFFARTH S,WORM K,et al.Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-smallcell lung cancer patients[J].PLoS One,2014,9(1):e85350.
[15]MARCHETTI A,DEL GRAMMASTRO M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment[J].PloS one,2014,9(8):e103883.
[16]PAILLER E,ADAM J,BARTHéLéMY A,et al.Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer[J].J Clin Oncol,2013,31(18):2273-2281.
[17]YU M,BARDIA A,ACETO N,et al.Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J].Science,2014,345(6193):216-220.
[18]NICOLAZZO C,RAIMONDI C,MANCINI M L,et al.Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J].Scientific Reports,2016,6:31726.
[19]CANCER GENOME ATLAS RESEARCH NETWORK.Comprehensive molecular profiling of lung adenocarcinoma[J].Nature,2014,511(7511):543-550.
[20]CANCER GENOME ATLAS RESEARCH NETWORK.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature,2012,489(7417):519-525.
[21]ABE H,KAWAHARA A,AZUMA K,et al.Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell(下转第3853页)lung carcinomas:A comparative study between small biopsy and excision samples[J].J Thorac Oncol,2015,10(5):800-805.
[22]KURUSU Y,YAMASHITA J,OGAWA M.Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer[J].Surgery,1999,126(5):820-826.
[23]WENDEL M,BAZHENOVA L,BOSHUIZEN R,et al.Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer:a glimpse into lung cancer biology[J].Physical biology,2012,9(1):016005.
[24]刘春花,杨政,李晶,等.小细胞肺癌患者循环肿瘤细胞检测的临床意义[J].实用医学杂志,2014,30(12):1906-1909.
[25]KREBS M G,HOU J M,SLOANE R,et al.Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches[J].JThorac Oncol,2012,7(2):306-315.
[26]BAYARRI-LARA C,ORTEGA F G,de Guevara A C L,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PloSOne,2016,11(2):e0148659.3848
[27]ZHANG Z,XIAO Y,ZHAO J,et al.Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer[J].Respirology,2016,21(3):519-525.
[28]CHINNIAH C,AGUARIN L,CHENG P,et al.Prospective trial of circulating tumor cells as a biomarker for early detection of recurrence in patients with locally advanced non-small cell lung cancer treated with chemoradiation therapy[J].Int J Radiat Oncol Biol Phys,2017,98(1):221.
[29]FUNAKI S,SAWABATA N,ABULAITI A,et al.Significance of tumour vessel invasion in determining the morphology of isolated tumour cells in the pulmonary vein in non-small-cell lung cancer[J].Eur J Cardio-Thorac,2012,43(6):1126-1130.
[30]MIYAMOTO D T,TING D T,TONER M,et al.Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity[C]//Cold Spring Harbor symposia on quantitative biology.Cold Spring Harbor Laboratory Press,2016,81:269-274.
[31]DEGELING K.The health economic impact of circulating tumour cells analysis in metastatic castration resistant prostate cancer treatment[J].Master Thesis,2015.
[2]ESPOSITO A,CRISCITIELLO C,LOCATELLI M,et al.Liquid biopsies for solid tumors:understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies[J].Pharmacol Ther,2016,157:120-124.
[3]GERLINGER M,ROWAN A J,HORSWELL S,et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J].New Engl J Med,2012,366(10):883-892.
[4]MATIKAS A,SYRIGOS K N,AGELAKI S.Circulating biomarkers in non-small-cell lung cancer:current status and future challenges[J].Clin Lung Cancer,2016,17(6):507-516.
[5]TARTARONE A,ROSSI E,LEROSE R,et al.Possible applications of circulating tumor cells in patients with non small cell lung cancer[J].Lung Cancer,2017,107:59-64.
[6]ASHWORTH T R.A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J].Aust Med J,1869,14:146.
[7]BULFONI M,TURETTA M,DEL BEN F,et al.Dissecting the heterogeneity of circulating tumor cells in metastatic breast cancer:going far beyond the needle in the haystack[J].Int J Mol Sci,2016,17(10).pii:E1775.
[8]ALIX-PANABIèRES C,PANTEL K.Challenges in circulating tumour cell research[J].Nat Rev Cancer,2014,14(9):623-631.
[9]ALIX-PANABIèRES C,PANTEL K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J].Cancer discov,2016,6(5):479-491.
[10]PéREZ-CALLEJO D,ROMERO A,PROVENCIO M,et al.Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring[J].Transl Lung Cancer Res,2016,5(5):455-465.
[11]TURETTA M,BULFONI M,BRISOTTO G,et al.Assessment of the mutational status of nsclc using hypermetabolic circulating tumor cells[J].Cancers,2018,10(8).pii:E270.
[12]MOK T S,WU Y L,AHN M J,et al.Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer[J].New Engl J Med,2017,376(7):629-640.
[13]PUNNOOSE E A,ATWAL S,LIU W,et al.Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:Association with clinical endpoints in a phase IIclinical trial of pertuzumab and erlotinib[J].Clin Cancer Res,2012,18(8):2391-2401.
[14]BREITENBUECHER F,HOFFARTH S,WORM K,et al.Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-smallcell lung cancer patients[J].PLoS One,2014,9(1):e85350.
[15]MARCHETTI A,DEL GRAMMASTRO M,FELICIONI L,et al.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment[J].PloS one,2014,9(8):e103883.
[16]PAILLER E,ADAM J,BARTHéLéMY A,et al.Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer[J].J Clin Oncol,2013,31(18):2273-2281.
[17]YU M,BARDIA A,ACETO N,et al.Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility[J].Science,2014,345(6193):216-220.
[18]NICOLAZZO C,RAIMONDI C,MANCINI M L,et al.Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J].Scientific Reports,2016,6:31726.
[19]CANCER GENOME ATLAS RESEARCH NETWORK.Comprehensive molecular profiling of lung adenocarcinoma[J].Nature,2014,511(7511):543-550.
[20]CANCER GENOME ATLAS RESEARCH NETWORK.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature,2012,489(7417):519-525.
[21]ABE H,KAWAHARA A,AZUMA K,et al.Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell(下转第3853页)lung carcinomas:A comparative study between small biopsy and excision samples[J].J Thorac Oncol,2015,10(5):800-805.
[22]KURUSU Y,YAMASHITA J,OGAWA M.Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer[J].Surgery,1999,126(5):820-826.
[23]WENDEL M,BAZHENOVA L,BOSHUIZEN R,et al.Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer:a glimpse into lung cancer biology[J].Physical biology,2012,9(1):016005.
[24]刘春花,杨政,李晶,等.小细胞肺癌患者循环肿瘤细胞检测的临床意义[J].实用医学杂志,2014,30(12):1906-1909.
[25]KREBS M G,HOU J M,SLOANE R,et al.Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches[J].JThorac Oncol,2012,7(2):306-315.
[26]BAYARRI-LARA C,ORTEGA F G,de Guevara A C L,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PloSOne,2016,11(2):e0148659.3848
[27]ZHANG Z,XIAO Y,ZHAO J,et al.Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer[J].Respirology,2016,21(3):519-525.
[28]CHINNIAH C,AGUARIN L,CHENG P,et al.Prospective trial of circulating tumor cells as a biomarker for early detection of recurrence in patients with locally advanced non-small cell lung cancer treated with chemoradiation therapy[J].Int J Radiat Oncol Biol Phys,2017,98(1):221.
[29]FUNAKI S,SAWABATA N,ABULAITI A,et al.Significance of tumour vessel invasion in determining the morphology of isolated tumour cells in the pulmonary vein in non-small-cell lung cancer[J].Eur J Cardio-Thorac,2012,43(6):1126-1130.
[30]MIYAMOTO D T,TING D T,TONER M,et al.Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity[C]//Cold Spring Harbor symposia on quantitative biology.Cold Spring Harbor Laboratory Press,2016,81:269-274.
[31]DEGELING K.The health economic impact of circulating tumour cells analysis in metastatic castration resistant prostate cancer treatment[J].Master Thesis,2015.